(adjective) : Showing no activity, growth, or current; sluggish. Lucrative (adjective) : Producing a great deal of profit.
Found in Paragraph E. The passage specifies that the World Health Organization advocates for the “One Health” approach to link human, animal, and environmental sectors. 12. Answer: viral pathologies
Paragraph C states: "Epidemiological projections indicate that if current trajectories remain unmitigated, drug-resistant infections could claim up to 10 million lives annually by 2050..." The phrase "claim up to 10 million lives annually" directly matches "future annual mortality rates." 2. Answer: B
(noun) : Microorganisms (like bacteria or viruses) that cause disease. (adjective) : Showing no activity, growth, or current;
A projection of the future annual death toll attributed to antimicrobial resistance.
What are the two main contributors to the rise of antibiotic-resistant bacteria?
Antibiotics, once a "miracle cure," are losing their effectiveness due to bacterial evolution through natural selection and horizontal gene transfer. The Causes: The crisis is driven by the misuse and overuse The passage specifies that the World Health Organization
Do the following statements agree with the information given in the Reading Passage? In boxes 6–9 on your answer sheet, write: if the statement agrees with the information FALSE if the statement contradicts the information NOT GIVEN if there is no information on this
The Growing Global Threat of Antibiotic Resistance: An IELTS Reading Guide
The text explicitly states that antibiotics in agriculture are administered "not to treat sickness, but to promote growth and prevent infections." Answer: B (noun) : Microorganisms (like bacteria or
Bacteria replicate and mutate extraordinarily quickly, allowing them to develop resistance to drugs much faster than scientists can produce new ones. Human Carelessness:
Using antibiotics for viral infections is a primary cause of resistance. 2. Matching Information
Second-line antibiotic treatments are generally safer and cheaper than first-line therapies.